Tectonic Therapeutic, Inc. (TECX)

Market Cap	563.43M +49.5%
Revenue (ttm)	n/a
Net Income	-83.49M
EPS	-4.46
Shares Out	18.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,680
Open	30.43
Previous Close	30.43
Day's Range	29.48 - 30.65
52-Week Range	14.39 - 36.03
Beta	n/a
Analysts	Strong Buy
Price Target	78.44 (+162.69%)
Earnings Date	May 7, 2026

About TECX

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPC...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: TECX
• Website: https://tectonictx.com

Analyst Summary

According to 10 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price target is $78.44, which is an increase of 162.69% from the latest price.

Price Target

$78.44

(162.69% upside)

Analyst Consensus: Strong Buy